Ovid outlined a pipeline targeting neural hyperexcitability, led by OV329, a next-generation GABA-aminotransferase inhibitor for drug-resistant focal onset seizures.
OV329 Phase 2 randomized controlled trial initiated, with topline results targeted for mid-2027; an open-label photo-paroxysmal response study also started.
Proof-of-concept safety and signal-finding studies in tuberous sclerosis complex seizures and infantile spasms planned to start in Q4 2026.
Phase 1 data cited strong tolerability at 7 mg, no treatment-related serious adverse events, no ophthalmic safety findings; once-daily dosing, no titration expected.
Ovid also advanced OV4071, an oral KCC2 direct activator, with Phase 1 proof-of-mechanism ongoing; ketamine challenge study slated for H2 2026.
OVID•
